Oppenheimer Positive on Regeneron Pharma (REGN), 'We anticipate material pipeline readouts in 2H22/1H23'

Regeneron Pharma (REGN) PT Raised to $647 at RBC Capital

RBC Capital analyst Kennen MacKay raised the price target on Regeneron Pharma (NASDAQ: REGN) to $647.00 (from $640.00) while maintaining a Sector Perform rating.... More

Regeneron Pharma (REGN) PT Raised to $655 at Cowen

Cowen analyst Tyler Van Buren raised the price target on Regeneron Pharma (NASDAQ: REGN) to $655.00 (from $645.00) while maintaining a Market Perform rating following earnings.

The analyst commented, "Strong Eylea and Dupixent sales led to good Q2 results. The primary focus... More

Regeneron (REGN) Tops Q2 EPS by $1.17

Regeneron (NASDAQ: REGN) reported Q2 EPS of $9.77, $1.17 better than the analyst estimate of $8.60. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.79 billion.

For earnings history and earnings-related data on Regeneron (REGN) click here.

Regeneron (REGN) Reports REGN5678 Shows Encouraging Anti-tumor Activity When Combined with PD-1 Inhibitor Libtayo

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced encouraging initial data from an ongoing Phase 1/2 trial investigating REGN5678, a novel PSMAxCD28 costimulatory bispecific antibody, in combination with the company's PD-1 inhibitor Libtayo® (cemiplimab) in advanced metastatic castration-resistant prostate cancer (mCRPC). REGN5678 is one of Regeneron's three clinical-stage costimulatory bispecifics, all of which are designed to bridge T cells to cancer cells and augment CD28 signaling to increase anti-tumor activity in combination with Libtayo or a CD3 bispecific.

"In past clinical trials, metastatic castration-resistant prostate cancer has been largely unresponsive to PD-1 inhibition and immunotherapy in... More